Press release
Deadline on Dec.23rd coming up for Investors in Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares
A Deadline is coming up on December 23, 2019 in the lawsuit for certain investors in Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
Investors who purchased shares of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) have certain options and there are strict and short deadlines running. Deadline: December 23, 2019. NASDAQ: ZYNE stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Eastern District of Pennsylvania the plaintiff alleges on behalf of purchasers of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) common shares between March 11, 2019, and September 17, 2019, that the defendants violated Federal Securities Laws.
More specifically, the plaintiff claims that between March 11, 2019, and September 17, 2019, the defendants made false and/or misleading statements and/or failed to disclose that Zygel was proving unsafe and not well-tolerated in the BELIEVE 1 Trial, that the foregoing created a foreseeable, heightened risk that Zynerba would fail to secure the necessary regulatory approvals for commercializing Zygel for the treatment of DEE in children and adolescents, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.
Those who purchased shares of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on Dec.23rd coming up for Investors in Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares here
News-ID: 1877317 • Views: …
More Releases from Shareholders Foundation
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc..
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Malvern, PA based Ocugen, Inc., a…
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp.
Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV…
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false…
More Releases for Zynerba
Explosive growth on New Psychoactive Substance Market 2021-2027| Zynerba Pharmac …
Leaders throughout the nation are looking for innovative methods to combat the increasing dependence crisis. As the most important treatment methods Prescription medicines designated as prohibited hazardous substances are generally accepted in different medical circumstances. Many prescription medications have pleasurable side effects which can attract patients to utilize these medicines for other applications than the approved ones. Prescription drug abuse or misuse may contribute to addictive behavior, the major risk…
Investigation announced for Long-Term Investors in shares of Zynerba Pharmaceuti …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Zynerba Pharmaceuticals, Inc.
Investors who are current long term investors in Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: ZYNE stocks follows a lawsuit filed against Zynerba Pharmaceuticals,…
Postoperative Management Market is Flourishing Worldwide || Boehringer Ingelheim …
The Global Postoperative Management Market is expected to reach USD 105.8 million by 2025, from USD 67.4 billion in 2017, growing at a CAGR of 5.8% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.
Get Exclusive Sample Copy of This Report Here https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-postoperative-management-market
Some of the major…
Lawsuit filed for Investors in NASDAQ: ZYNE shares over alleged Securities Laws …
An investor, who purchased shares of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), filed a lawsuit over alleged Securities Laws violations by Zynerba Pharmaceuticals, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2019. NASDAQ: ZYNE investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call…
Fibromyalgia Drugs Market Size, Status, Executive Summary, Regional Analysis, Ou …
The global market status for Fibromyalgia Drugs Market is precisely examined through a smart research report added to the broad database managed by Market Research Hub (MRH). This study is titled “Global Fibromyalgia Drugs Market” Size, Status and Forecast 2019-2025, which tends to deliver in-depth knowledge associated to the Fibromyalgia Drugs Market for the present and forecasted period until 2025. Furthermore, the report examines the target market based on market…
Cannabinoids Therapeutics-Pipeline Analysis 2018, Clinical Trials & Results | GW …
Cannabinoid is a type of alkaloid that is obtained from the cannabis sativaplants. Cannabis, also known as marijuana, produce resin containing compounds known as cannabinoids. Cannabinoids are being used for medical purposes from the ancient times. These are the active substance in Cannabis plants that produce pharmacological actions in the body that mostly involves central nervous system and immune system. Delta-9-THC (tetrahydrocannabinol) is the main active component of cannabinoids.
Download the…
